CUE Cue Biopharma, Inc.

NASDAQ
$31.41

Cue Biopharma, Inc. (CUE) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $4.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.8% since its last earnings release on August 14, 2026.

Cue Biopharma Reported Earnings
Friday, August 14, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($4.04)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $29.47

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Charts powered in part by Lightweight Charts™ by TradingView.